Files detailed response to Form 483 observations
Divis Laboratories announced that its has filed its detailed response to the 'Form 483' observations of the US-FDA for the Company's unit at Visakhapatnam within the time permitted.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
